David Sinclair Plans to Test Whole-Body Rejuvenation Drug in $101M XPrize Competition

David Sinclair Bets on an Oral Drug to Reverse Aging in the $101 Million XPrize

For years, Harvard biologist and longevity researcher David Sinclair has made a bold prediction: one day, you'll walk into your doctor's office and walk out with a prescription that makes you biologically 10 years younger. That vision, once dismissed by mainstream scientists as science fiction, is now inching closer to a real-world test. According to MIT Technology Review, Sinclair is preparing to launch human trials of an oral "reprogramming" drug as part of the $101 million XPrize Healthspan competition — one of the most ambitious longevity challenges ever organized.

The announcement marks a significant escalation in Sinclair's long-running effort to move aging science out of the laboratory and into the clinic. But it also arrives at a moment when the broader field of age reversal is facing hard questions about safety, effectiveness, and whether scientists can even agree on how to measure aging in the first place.

What Is the XPrize Healthspan Competition?

The XPrize Foundation, known for funding moonshot competitions in aerospace and ocean exploration, launched its Healthspan prize to push the boundaries of human longevity science. The foundation is offering cash awards to research teams that can demonstrate they have meaningfully "restored" a person to an earlier biological age — not just in one organ or tissue, but across multiple systems simultaneously.

To win the grand prize, a team must show a relative improvement of 10 years or more in three distinct biological categories: immune function, cognitive function, and muscle function. This multi-system requirement is intentional. It reflects a growing scientific consensus that true rejuvenation cannot be limited to a single biomarker or tissue type — it must be systemic, measurable, and reproducible.

Dozens of teams from around the world are reportedly competing, bringing with them an array of interventions ranging from stem cell therapies to lifestyle-based protocols. Sinclair's entry, however, is drawing particular attention because of both his public profile and the novelty of his proposed approach.

Introducing SL-100: A Drug That Mimics Reprogramming Genes

Sinclair's candidate drug is code-named SL-100. Unlike gene therapy approaches that introduce new genetic material into the body, SL-100 is a chemical compound designed to be taken orally. Its goal is to mimic the effects of a set of reprogramming genes — most notably the Yamanaka factors — that have been shown in laboratory settings to reset the epigenetic "age" of cells.

The concept of cellular reprogramming traces back to Nobel Prize-winning work by Shinya Yamanaka, who discovered that introducing four specific genes into adult cells could revert them to a stem-cell-like state. Over the past decade, researchers including Sinclair have been exploring whether partial reprogramming — activating these genes briefly rather than fully — could reverse the biological signs of aging without causing cells to lose their identity or become cancerous.

SL-100 takes this concept a step further by attempting to achieve the same epigenetic reset using small molecules rather than genetic tools. If it works as intended, a patient could theoretically swallow a pill and trigger a body-wide rollback of cellular aging — no injections, no viral vectors, no surgery required.

What the Science Says — and Where Caution Is Warranted

Not everyone in the scientific community is ready to celebrate. Several researchers working in the reprogramming field have noted that chemical approaches to epigenetic rejuvenation have historically run into a frustrating problem: at low doses, the compounds tend to produce little or no measurable effect, while at higher doses they can become outright toxic.

There is also the matter of transparency. As of now, Sinclair's supporting animal data for SL-100 has not been published in a peer-reviewed journal, meaning it has not yet faced independent scientific scrutiny. While unpublished preclinical data is not unusual at early stages of drug development, it does make it difficult for outside experts to assess how strong the case for moving to human testing actually is.

Critics have also pointed out that Sinclair's track record includes high-profile claims — most notably around the longevity molecule NMN and the protein sirtuin — that were later disputed or significantly walked back by other researchers. Supporters argue that Sinclair's willingness to take scientific risks is precisely what the field needs, and that the XPrize framework will at least ensure results are measured against an agreed-upon standard.

The Deeper Problem: How Do You Measure Aging?

Perhaps the most underappreciated challenge facing every team in the XPrize competition — including Sinclair's — is a deceptively fundamental one: scientists still cannot fully agree on how to reliably measure biological age or confirm that it has been reversed.

Tools like epigenetic clocks, which analyze chemical modifications to DNA to estimate biological age, have become widely used in longevity research. But these clocks were designed to predict age-related disease and mortality, not necessarily to confirm true biological rejuvenation. A drug that shifts an epigenetic clock reading by several years may or may not translate into meaningful improvements in how a person actually functions, feels, or ages over time.

In this sense, the XPrize competition is as much about establishing a scientific language for measuring aging as it is about crowning a winner. The requirement to demonstrate improvements in immune, cognitive, and muscle function — rather than relying solely on molecular biomarkers — reflects an attempt to anchor rejuvenation claims in observable, functional outcomes.

Why This Moment Matters for Longevity Science

Regardless of whether SL-100 succeeds or fails, Sinclair's entry into the XPrize race signals something important about where longevity science is heading. The field is moving, however imperfectly, from theoretical frameworks and animal models toward human trials with real accountability structures.

• Increased investment: The $101 million prize pool is drawing serious capital and talent into aging research, accelerating timelines that might otherwise stretch across decades.
• Standardization pressure: The competition is forcing teams to agree on measurable endpoints, which could help resolve long-standing disputes about how to define and detect biological age reversal.
• Public visibility: High-profile entries like Sinclair's bring mainstream attention to longevity science, which can influence funding, regulatory interest, and public expectations — for better or worse.
• Safety scrutiny: The human trial phase will generate safety data that simply does not exist yet for many of these chemical reprogramming approaches.

Whether David Sinclair's oral rejuvenation drug ultimately fulfills his decades-long prediction remains to be seen. But the XPrize competition is ensuring that the answer — whatever it turns out to be — will be tested in public, measured against a defined standard, and scrutinized by a scientific community that is watching very closely. For anyone interested in the future of human aging, the next few years are going to be worth paying attention to.